KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Aquestive Therapeutics (AQST) EBIAT (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of EBIAT data on record, last reported at -$31.9 million in Q4 2025.

  • For Q4 2025, EBIAT fell 86.81% year-over-year to -$31.9 million; the TTM value through Dec 2025 reached -$83.8 million, down 89.83%, while the annual FY2025 figure was -$83.8 million, 89.83% down from the prior year.
  • EBIAT reached -$31.9 million in Q4 2025 per AQST's latest filing, down from -$15.4 million in the prior quarter.
  • Across five years, EBIAT topped out at $8.1 million in Q1 2023 and bottomed at -$31.9 million in Q4 2025.
  • Average EBIAT over 5 years is -$13.0 million, with a median of -$13.0 million recorded in 2022.
  • Peak YoY movement for EBIAT: surged 161.03% in 2023, then crashed 465.55% in 2024.
  • A 5-year view of EBIAT shows it stood at -$28.9 million in 2021, then skyrocketed by 57.33% to -$12.4 million in 2022, then skyrocketed by 34.33% to -$8.1 million in 2023, then crashed by 110.27% to -$17.1 million in 2024, then crashed by 86.81% to -$31.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIAT were -$31.9 million in Q4 2025, -$15.4 million in Q3 2025, and -$13.5 million in Q2 2025.